Library >> Browse Articles >> Cancers
PSA screening cuts prostate cancer deaths by a fifth
MedWire News: The risk of death from prostate cancer is reduced by 20% with prostate-specific antigen (PSA)-based screening, although there is also a high risk for overdiagnosis, the results of a pan-European study indicate. The impact of PSA-based screening on prostate cancer morality remains unclear, despite the known benefits in terms of detecting early prostate cancer. Consequently, the European Randomized Study of Screening for Prostate Cancer (ERSPC) was started in the 1990s.